# Trevena (TRVN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/TRVN
## Company Profile
- Ticker: TRVN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 0.001 USD
- Market cap: Not available USD
- Last updated: 2026-08-26
## Business Overview
Trevena was a specialty neuroscience and pain company focused on opioid-sparing and CNS therapeutics. Its story centered on difficult pain and neurologic indications where commercial uptake depends on both clinical differentiation and regulatory execution.
## Why The Stock Is Moving

Current closing-price context is not available for TRVN.

## Geographic Base

Trevena was headquartered in the United States and listed on NASDAQ, placing it in the small-cap biopharmaceutical category. It sat in the high-risk neuroscience and pain niche rather than broad healthcare.

## Business Model

The business model was driven by late-stage development, product commercialization attempts, and the ability to secure reimbursement and physician adoption. Investors watched clinical data, product launches, and the company's capital structure closely.

## Landscape Position

Trevena occupied a catalyst-sensitive small-cap CNS niche. It is best viewed as a legacy specialty-pharma story where execution risk and funding pressure were always central to the stock.

## Future Catalysts

- Trevena is now mostly a legacy / closeout story, so the catalysts are any remaining asset or strategic update rather than a fresh development milestone. The market no longer treats it as a live growth name.

## Recent News
- 2024-11-07 12:01 EST — [Trevena Reports Third Quarter 2024 Results and Provides Business Update](https://biopharmsignal.com/news/TRVN/trevena-reports-third-quarter-2024-results-and-provides-business-update) — Source: Trevena
- 2024-10-04 20:05 EST — [Trevena Announces Receipt of Nasdaq Delisting Notification](https://biopharmsignal.com/news/TRVN/trevena-announces-receipt-of-nasdaq-delisting-notification) — Source: Trevena
- 2024-08-08 20:05 EST — [Trevena Announces Reverse Stock Split](https://biopharmsignal.com/news/TRVN/trevena-announces-reverse-stock-split) — Source: Trevena
- 2024-08-08 11:00 EST — [Trevena Reports Second Quarter 2024 Results and Provides Business Update](https://biopharmsignal.com/news/TRVN/trevena-reports-second-quarter-2024-results-and-provides-business-update) — Source: Trevena
- 2024-07-08 13:15 EST — [Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing](https://biopharmsignal.com/news/TRVN/trevena-announces-2m-non-dilutive-financing-tranche-and-reduction-in-outstanding-liabilities-in-connection-with-existing-ex-us-royalty-financing) — Source: Trevena